logo-loader
RNS
Hikma Pharmaceuticals PLC

Hikma Pharmaceutical - Director/PDMR Shareholding

RNS Number : 5563Y
Hikma Pharmaceuticals Plc
22 August 2018
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bassam Kanaan

2

Reason for the notification

a)

Position/status

Chief Strategy and Corporate Development Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Disposal of 30,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC.

c)

Price(s) and volume(s)

Price(s): £19.17

Volume(s): 30,000

d)

Aggregated information

Aggregated volume: 30,000

Price: £575,100

e)

Date of the transaction

20 to 21 August 2018

f)

Place of the transaction

London Stock Exchange (XLON)

Peter Speirs, Company Secretary, Responsible for releasing this announcement

22 August 2018


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHGIGDICXDBGID
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read